21 May 2009
Evolution of bone disease in patients during the first 2 years after transplantation; a prospective single centre study
K Falkiewicz, M Boratyńska, S Zmonarski, A Milewicz, D Patrzałek, P Biecek, M KlingerAnn Transplant 2009; 14(1): 34-35 :: ID: 880323
Abstract
Background: Post-transplant bone disease is caused by renal osteodystrophy
acquired during HD, immunosuppressive drugs and metabolic factors after transplantation. Aim: to examine bone mineral density (BMD) and to identify factors preventing bone loss in patients in the first 2 years post transplant.
Material/Methods: 90 renal allograft recipients (age 42.7±11.4 years), treated with cyclosporine/tacrolimus, azathioprine/MMF and prednisone were included in the study. BMD measurements in lumbar spine and femur (femoral neck, Ward's and Trochanteric region) were performed by DEXA in the third month
and every 6 months for 2 years after transplantation. Markers of bone remodelling (intact parathyroid hormone [iPTH], calcitriol, osteocalcine, carboxyterminal telopeptide of type-I collagen) were assayed on the third day, 1[sup]st[/sup] month and every 6 months.
Results: In the initial measurement, osteopenia was found in 35% in the lumbar region and 52% in femur; osteoporosis in 8.3% (according o the WHO classification). Prevalence of osteopenia increased during the first year, then decreased to initial value, but the frequency of osteoporosis did not change (8.3 vs. 6.0%). BMD and Z-score decreased during first and increased in the second year; 27% patients achieved initial values and 38% higher than initial values. BMD gain in lumbar spine and femur was found in patients with significantly higher calcitriol level during first six months (P<0.01); higher osteocalcin level (P<0.05); higher eGFR during 1 to 24 months and treated with tacrolimus. Improvement of lumbar BMD occurred in younger patients (38 vs. 46 years; P<0.027). BMD gain in femur correlated with higher level of iPTH from 1-12 months (P<0.01);. Patients treated with tacrolimus had significantly higher Z-score in lumbar spine and femur at 24 month in comparison to cyclosporine treatment (p<0.05).
Conclusions: Two years after transplantation >60% of patients showed stability or gain in the bone mass. Sufficient calcitriol level in early post transplant period, adequate iPTH, renal efficiency and tacrolimus treatment prevent progression of the post-transplant bone disease.
Keywords: Immunosuppression, Kidney Transplantation
In Press
18 Mar 2024 : Original article
Does Antibiotic Use Increase the Risk of Post-Transplantation Diabetes Mellitus? A Retrospective Study of R...Ann Transplant In Press; DOI: 10.12659/AOT.943282
20 Mar 2024 : Original article
Transplant Nephrectomy: A Comparative Study of Timing and Techniques in a Single InstitutionAnn Transplant In Press; DOI: 10.12659/AOT.942252
28 Mar 2024 : Original article
Association Between FEV₁ Decline Rate and Mortality in Long-Term Follow-Up of a 21-Patient Pilot Clinical T...Ann Transplant In Press; DOI: 10.12659/AOT.942823
02 Apr 2024 : Original article
Liver Transplantation from Brain-Dead Donors with Hepatitis B or C in South Korea: A 2014-2020 Korean Organ...Ann Transplant In Press; DOI: 10.12659/AOT.943588
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860